Long-term Safety Results of Epicutaneous Immunotherapy (EPIT) with Viaskin Peanut in Peanut-Allergic Children Aged 4-11 Years in the Phase 3 PEOPLE Study
Previously reported interim results from PEOPLE (PEPITES Open-Label Extension) demonstrated Viaskin Peanut 250 μg (VP250) led to continued treatment response and was well-tolerated out to 3 years. Here we report PEOPLE end-of-study safety results.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: David Fleischer, Lara Ford, Gordon Sussman, William Yang, Peter Smith, Jacqueline Pongracic, Roxanne Oriel, Hugh Sampson Source Type: research